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Short Form of the Valued Life Activities
Disability Questionnaire for Rheumatoid Arthritis
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ANAGHA NADKARNI,4 LISA ROSENBLATT,4 ROSS MACLEAN,4 AND AFTON L. HASSETT5
Objective. To develop and validate a shortened version of the Valued Life Activities disability and accommodations scale
(VLA) for individuals with rheumatoid arthritis (RA).
Methods. To shorten the existing VLA measure, item response theory analyses were conducted using data from 449
patients with RA. Next, the resulting 14-item shortened version of the VLA scale (S-VLA) was evaluated by structured
interviews among 20 RA patients. Lastly, the S-VLA was administered to 150 RA patients along with other measures,
including the Health Assessment Questionnaire (HAQ) and Short Form 36 (SF-36). A random sample of 50 patients
completed the S-VLA 2 weeks later to assess reliability. Item statistics were calculated to evaluate correlations between
individual items and the S-VLA total score. Correlations between the S-VLA and other measures were used to evaluate
validity.
Results. Test–retest reliability was 0.91, while Cronbach’s alpha for the S-VLA was 0.95. None of the 14 items was
associated with improved alpha coefﬁcients when omitted. All of the items were strongly correlated with the S-VLA total
score. S-VLA scores were highly positively correlated with the HAQ (r 0.81, P< 0.001), patient-reported disease activity
(r  0.71, P < 0.001), satisfaction with abilities (r  0.82, P < 0.001), and number of days with activity limitations (r 
0.65, P < 0.001). In addition, as hypothesized, the S-VLA was inversely correlated with the SF-36 physical component
summary score (r  0.78, P < 0.001) and the physical functioning (r  0.80, P < 0.001), role physical (r  0.67,
P < 0.001), and social functioning (r  0.72, P < 0.001) subscales.
Conclusion. The S-VLA is a short, valid, and reliable instrument that may prove useful for monitoring disability among
individuals with RA.
INTRODUCTION
Functional impairment and disability are primary mani-
festations of rheumatoid arthritis (RA). Functioning is
most commonly measured among individuals with RA by
the Health Assessment Questionnaire (HAQ) (1). Evidence
generally indicates a high degree of reliability and validity
for the HAQ (2,3), although it has demonstrated question-
able response to change in some groups (4,5). Addition-
ally, some have suggested that the HAQ has limited rele-
vance to day-to-day life because difﬁculty with speciﬁc
physical actions is queried rather than difﬁculty with ac-
tivities. Finally, the HAQ measures fairly low-level func-
tioning such as toileting and eating, whereas functional
goals of most persons with RA are to maintain high-level
functioning such as participating in social and recreational
activities.
Use of assistive devices or equipment and personal as-
sistance has been shown to reduce disability (6–8), and
both assistive devices and personal assistance appear to be
widely used by individuals with arthritis. The importance
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of assistive devices and personal assistance to functioning
among individuals with RA is reﬂected by the assessment
of accommodations in the HAQ. However, other behav-
ioral accommodations to improve functioning or reduce
disability, such as limiting activities or taking more time to
perform them, may be more commonly used than assistive
devices or personal assistance (6–10). Therefore, there is a
need for a measure that can address a wide range of func-
tioning, and also address behavioral accommodations that
are frequently adopted by individuals with RA to improve
their function.
The Valued Life Activities disability and accommoda-
tions scale (VLA) measures a broader range of activities
than traditional disability measures, such as the HAQ
(11,12). The theoretical basis of the VLA is the disable-
ment model proposed by Verbrugge et al (13–15). Ver-
brugge et al proposed that life activities be grouped into 3
categories: obligatory activities, required for survival and
self-sufﬁciency, including activities such as hygiene and
self-care, walking inside, walking outside, and using trans-
portation or driving; committed activities, associated with
one’s principal productive social roles, such as paid work,
household responsibilities, and child and family care; and
discretionary activities, such as socializing, exercising, en-
gaging in leisure time activities and pastimes, pursuing
volunteer work or hobbies, or other activities in which
individuals engage for relaxation and pleasure. The VLA
assesses difﬁculty in this broad array of activities. Items
can also be included in the VLA to assess use of behavioral
accommodations in each activity (10).
To date, more than 1,200 persons with rheumatic dis-
eases have completed the VLA, but its length (15–20 min-
utes to complete) may inhibit application in large clinical
trials and routine practice. A brief version of the VLA
might be more feasible to use in both clinical settings and
as an outcome measure for intervention studies. Therefore,
the primary objective of this study was to develop and
validate a shortened version of the VLA (S-VLA) for RA,
while maintaining the coverage of the broad spectrum of
activities included in the VLA.
MATERIALS AND METHODS
This was a 3-phase project. Phase 1 focused on item re-
duction to shorten the existing VLA. Phase 2 consisted of
a pilot test to ensure readability, relevance, and compre-
hension of items and instructions of the new shortened
measure. In Phase 3, a formal test of the new measure was
conducted to estimate reliability and validity in a clinical
setting.
Development and validation of the original VLA scale.
Development of the VLA has been described in detail
previously (11). Brieﬂy, the VLA scale was developed
based on time/budget studies to determine the impact of
arthritis (16), and has been modiﬁed and reﬁned over the
past decade. Respondents have been asked over multiple
waves to identify activities or activity domains in addition
to those queried that have been affected by their condition.
Revisions have been made to the VLA scale based on those
accumulated responses as well as analysis of previous
versions of the scale. The version of the VLA scale used in
the current analyses includes 34 activity domains. Respon-
dents rate the difﬁculty of performing each activity, using
a 4-point scale corresponding to the response scale of the
HAQ (0 [no difﬁculty] to 3 [unable to perform]). Activities
that participants deem unimportant to them or activities
that they do not perform for reasons unrelated to RA are
not rated and are not included in scoring.
In addition to rating the difﬁculty in performing each
activity, the participants are also asked whether they make
4 types of behavioral accommodations for the activity:
limitations in the amount or kind of activity within the
domain, taking more time to perform activities, needing
help from another person, and using special devices or
aids. A scoring method for the VLA incorporating the use
of accommodations has been developed and reported (10).
In the present study, scoring on both long and short
versions took into account use of behavioral accommoda-
tions, as previously reported (10). Items with no difﬁculty
and no accommodations received scores of 0, items with
no difﬁculty but with use of any accommodation received
scores of 1, and items with a little difﬁculty, with a lot of
difﬁculty, or that participants were unable to perform re-
ceived scores of 2, 3, and 4, respectively, regardless of use
of accommodations. The total S-VLA score is calculated as
the mean difﬁculty of all activities rated.
Phase 1: item reduction. Subjects. Phase 1 entailed
analysis of existing data from 2 waves of the Univer-
sity of California, San Francisco RA Panel. RA Panel mem-
bers were originally recruited in 1982–1983 from a ran-
dom sample of rheumatologists practicing in Northern
California (n  822). There were subsequently 4 addi-
tional enrollment periods in 1989–1990, 1995, 1999, and
2003, during which 203, 131, 122, and 169 individuals
were enrolled, respectively. Retention from year to year
has averaged 93%; the 7% attrition includes deaths. The
Signiﬁcance & Innovations
● The Valued Life Activities disability and accom-
modations scale (VLA) measures a broader range
of activities than traditional disability measures,
such as the Health Assessment Questionnaire, is
more closely related to satisfaction with function-
ing and psychological well-being than other mea-
sures of function, and items can also be included
to assess the use of behavioral accommodations in
these activities.
● However, to date, the VLA scale has been used
predominantly as an academic research instru-
ment mostly because the VLA requires approxi-
mately 15 minutes to complete.
● We developed a short version of the VLA, the
S-VLA, that is valid, reliable, and conducive to use
in clinical settings, as it requires only 2–4 minutes
to complete.
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principal data source for the RA Panel is an annual tele-
phone interview. In years 1 and 2 of the current analyses
there were 449 and 421 participants, respectively. Char-
acteristics of the RA Panel during year 1 are shown in
Table 1. Analyses were ﬁrst conducted with year 1 data
and then validated with year 2 data.
Procedures and analyses. Item response theory (IRT)
analyses using ConQuest were conducted to reduce the
number of items while still covering the range of activity
“difﬁculty” (e.g., from low-level activities such as self-care
to high-level activities such as physical recreation). Items
were deleted based on misﬁt (weighted mean square sta-
tistic0.75 or1.34 and t-statistics less than2 or greater
than 2), logit values that duplicated information pro-
vided by other items at similar logit values, and substan-
tive considerations.
Psychometric properties of the S-VLA were compared
to those of the original longer version. Internal consis-
tency of each version was assessed with Cronbach’s alpha.
Analyses were conducted to establish construct validity by
examining correlations of VLA and S-VLA with the fol-
lowing 3 measures, each of which is theoretically related
to the construct of valued life activity disability.
The HAQ was developed speciﬁcally for and validated
in patients with arthritis (1). Respondents rate the difﬁ-
culty posed by speciﬁc actions on a 0–3 scale (where 0 
no difﬁculty, 1  some difﬁculty, 2 much difﬁculty, and
3  unable to perform). Items also assess the need for
assistance from others and use of assistive devices. A score
ranging from 0 to 3 can be calculated.
The overall impact of RA was measured with a single
item (“Considering all the ways your arthritis affects you,
rate how well you are doing”), rated from 0 (very poorly) to
100 (very well).
Each of the questions for the extent to which RA affects
“things you NEED to do” and the extent to which RA
affects “things you LIKE to do” was rated on a 0–3 scale
(where 0  not at all, 1  a little, 2  a moderate amount,
and 3  a great deal).
Phase 2: pilot test of S-VLA. Subjects. Twenty RA
patients from the University of Medicine and Dentistry
of New Jersey Robert Wood Johnson Medical School
(UMDNJ-RWJMS) rheumatology clinic completed the S-VLA
questionnaire. All of the participants met the American
College of Rheumatology (ACR) criteria for RA (17), had a
diagnosis of RA for at least 6 months, had no alternate
diagnosis that contributed signiﬁcantly to disability (e.g.,
Parkinson’s disease, multiple sclerosis, metastatic cancer),
were ﬂuent in English, and were present at the clinic for a
routine visit to their rheumatologist. Study-related proce-
dures were carried out by trained research assistants.
Procedures. Subjects were asked to read the directions
associated with the S-VLA and complete the question-
naire. No other explanations about completing the ques-
tionnaire were offered, although subjects could ask ques-
tions if the instructions were unclear. Inquiries related to
the S-VLA were recorded and considered before the larger
validation study (phase 3) was initiated. Once the ques-
tionnaire was completed, the subject participated in a
structured cognitive debrieﬁng interview, which queried
instruction clarity, item clarity, adequacy of response op-
tions, opinion regarding how well each item addressed the
activity in question, and whether the S-VLA, as a whole,
adequately measured activity limitations. Patients were
paid for participation in the phase 2 interview. Procedures
were approved by the UMDNJ-RWJMS Institutional Re-
view Board, and all of the participants provided written
informed consent.
Analyses. Phase 2 analyses focused on the clarity of the
S-VLA instructions and items, adequacy of response op-
tions, relevance and comprehensiveness of the items, and
appearance and format of the questionnaire.
Phase 3: validation study. Subjects. For phase 3, 150
patients with RA were recruited from the UMDNJ-RWJMS
rheumatology clinic and several other clinics in the com-
munity; characteristics are shown in Table 1. All of the
patients met ACR criteria for RA (17), had a diagnosis of
RA for at least 6 months, had no alternate diagnosis that
contributed signiﬁcantly to disability, were ﬂuent in Eng-
lish, and were at the clinic for a routine visit to their
rheumatologist. No patients who participated in phase 2
participated in phase 3. All study-related procedures were
carried out by trained research assistants. Patients were
paid for participation in phase 3. Procedures were ap-
proved by the UMDNJ-RWJMS Institutional Review Board,
and all of the participants provided written informed
consent.
Table 1. Characteristics of samples*
Phase 1:
UCSF RA Panel
(n  449)
Phase 3:
validation sample
(n  150)
Women, % (no.) 85.1 (382) 74.0 (111)
Age, mean  SD years 59.2  12.9 55.7  14.6
White non-Hispanic race/ethnicity,
% (no.)
74.8 (336) 62.0 (93)
Duration of RA, mean  SD years 18.3  11.7 12.7  11.5
HAQ score, mean  SD 1.09  0.74 1.09  0.77
* UCSF  University of California, San Francisco; RA  rheumatoid arthritis; HAQ  Health Assessment
Questionnaire.
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Procedures. Subjects completed the S-VLA, in addition
to several other questionnaires, described below, and a
demographics form. The S-VLA was administered ﬁrst
with the additional questionnaires in random order. Sub-
jects were asked to read the directions associated with the
questionnaires and complete them. No other explanations
about completing the questionnaires were offered, al-
though the subjects were allowed to ask questions if the
instructions were unclear. A random sample of 50 respon-
dents was asked to complete the questionnaires 2 weeks
later, to assess test–retest reliability. Questionnaires were
mailed to these individuals.
Measures. Formatting of the S-VLA was modiﬁed prior
to phase 3 based on subject feedback during phase 2. The
S-VLA is shown in Supplementary Appendix A (available
in the online version of this article at http://onlinelibrary.
wiley.com/journal/10.1002/(ISSN)2151-4658).
To assess the construct validity of the S-VLA, the HAQ
(described above) and several additional questionnaires
were administered.
The Short Form 36 health survey (SF-36) is a self-report
questionnaire consisting of 36 items aggregated to score 8
subscales related to physical and mental health (18,19).
The subscales can be combined to yield a physical com-
ponent summary (PCS) score and a mental component
summary score. The PCS and 3 subscales, i.e., role emo-
tional, social functioning, and role physical, were used in
this study because they were judged by the investigators to
possess properties associated with VLA disability and gen-
eral role functioning. The SF-36 summary scales and sub-
scales have demonstrated excellent reliability and validity
(18,19).
The Rheumatoid Arthritis Disease Activity Index
(RADAI) is a patient-assessed measure of RA disease ac-
tivity (20,21). It queries global disease activity in the past
6 months, current disease activity in terms of swollen and
tender joints, arthritis pain, duration of morning stiffness,
and painful joints rated on a joint list. Scores range from
0–10, with higher scores reﬂecting greater disease activity.
Ample evidence exists supporting the reliability and va-
lidity of the RADAI (22).
The Satisfaction with Abilities and Well-Being Scale
(SAWS) is a 13-item self-report questionnaire developed
to assess satisfaction with abilities and well-being in pa-
tients with RA (23). It assesses 13 domains (e.g., work,
home maintenance, social participation) and has a total
score plus subscales scores for satisfaction with activities
and satisfaction with well-being. The overall SAWS has
demonstrated good validity and internal consistency
(Cronbach’s   0.93), as have the 2 subscales (activities:
  0.91 and well-being:   0.82).
Two questions are included in the Activity Participation
Questionnaire (APaQ): “During the past 30 days, on about
how many days did your rheumatoid arthritis keep you
from doing your usual activities?” and “During the past
30 days, how often were you able to perform your usual
activities completely, in spite of your rheumatoid arthri-
tis?” (24). We included only the number of days with
activity limitations in our analyses. The APaQ has been
found to have good internal consistency (Cronbach’s  
0.70) and acceptable test–retest reliability (intraclass cor-
relation coefﬁcient 0.60). Construct validity and sensitiv-
ity to changes in patient activity levels have also been
demonstrated.
Analyses. Internal consistency was determined with
Cronbach’s alpha. Unidimensionality was assessed using
an exploratory bifactor model, which features a compari-
son of a single-factor model to a model with a general
factor and group factors (25). Test–retest reliability was
evaluated in the subgroup of participants that completed
the 2-week followup questionnaires by correlating S-VLA
scores from the 2 administrations and by calculating Krip-
pendorff ’s alpha coefﬁcients of reliability for individual
item responses (ordinal scale) (26). Item statistics were
then calculated to examine the correlations between indi-
vidual items and the total S-VLA score, while also correct-
ing for overlap and scale reliability. Construct validity of
the S-VLA was assessed via correlations with the other
measures. T-tests compared responses of men and women
and of individuals with early (25 months) and later
(25 months) RA.
RESULTS
Phase 1. IRT analyses. Partial credit and rating scale
models were both tested; the partial credit model had
fewer item and step misﬁts (G2 likelihood ratio  623.881,
Table 2. Phase 1: item response theory analysis of S-VLA*
EAP
reliability† Cronbach’s 
Correlation with
HAQ‡
Overall
rating of
RA impact§
RA affects
things you
NEED to do¶
RA affects
things you
LIKE to do¶
VLA 0.949 0.97 0.79 0.54 0.74 0.65
S-VLA 0.932 0.94 0.83 0.56 0.74 0.66
* VLA and S-VLA scores range from 0–4, with higher scores reﬂecting greater disability. S-VLA  shortened version of the VLA; EAP  expected a
posteriori prediction; HAQ  Health Assessment Questionnaire; RA  rheumatoid arthritis; VLA  Valued Life Activities disability and accommo-
dations scale.
† EAP reliability explains the degree to which predictions of an individual’s ability have improved, and range from 0–1, with higher estimates
reﬂecting greater reliability.
‡ HAQ scores range from 0–3, with higher scores reﬂecting greater functional limitations.
§ Ratings of the overall impact of RA ranged from 0–100, with lower scores reﬂecting greater impact.
¶ Ratings ranged from 0–3, with higher scores reﬂecting greater effect.
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P  0.0001). Item deletions were made progressively, re-
sulting in a 21-item version, a 14-item version, and 4
12-item versions. For both analytic and conceptual rea-
sons, the 14-activity version of the VLA questionnaire was
selected as the ﬁnal S-VLA version. The 14-item S-VLA
had 0 misﬁtting steps; 2 items had potential misﬁt but
were retained to provide logit spread and for substantive
reasons, speciﬁcally, to ensure that a balance of items
measuring obligatory, committed, and discretionary activ-
ities and that items representing the full range of activity
difﬁculty were included. Expected a posteriori prediction
reliability was excellent for both versions (0.949 for the
VLA, 0.932 for the S-VLA) (Table 2).
Other analyses. Correlation between the VLA and S-
VLA scores was 0.97. Internal consistency was excellent
for both measures (VLA: 0.97, S-VLA: 0.94) (Table 2).
Correlations of the S-VLA with other measures of function-
ing and RA impact were similar in magnitude to correla-
tions of the VLA with the same measures; all of the corre-
lations were in the expected directions. All analyses were
repeated with year 2 data, and all results were conﬁrmed.
Phase 2. Twenty patients with RA completed the cog-
nitive interviewing process. Participants were largely
women (80%) and married (55%), with a mean SD age of
52  13 years. Twenty percent of the participants were
Hispanic, 15% were African American, 5% were Asian,
and 55% were white. Just over one-half (55%) were em-
ployed full time and 70% reported a household income of
more than $50,000 a year. The mean  SD duration of
illness was 9  8 years.
Overall reaction to the S-VLA was positive; only 1 pa-
tient indicated that he/she did not like the instrument.
Because 2 of the ﬁrst 5 patients reported that the instruc-
tions were not clear and another found the response
options confusing, the instructions and formatting were
slightly modiﬁed for interviews with the remaining 15
patients. After modiﬁcation, 14 of 15 patients interviewed
reported the instructions to be clear and the response
options to be clear and adequate; all 15 reported that the
items were easy to understand. Respondents were also
asked to rate whether each item assessed the ability to
Table 4. Phase 3: response patterns for S-VLA items*
No.
rating
item
Difﬁculty rating response frequency, %
% reporting an
accommodation
Mean score
(adjusted for
accommodations)†
0
(no difﬁculty)
1
(some difﬁculty)
2
(a lot of
difﬁculty)
3
(unable to
perform) Total
Of those
reporting no
difﬁculty
1. Basic needs 150 47 46 6 1 44 6 1.18
2. Meal preparation 140 47 41 9 2 41 5 1.21
3. Light housework 141 52 38 6 4 37 6 1.13
4. Heavier housework 144 22 42 26 10 52 6 2.06
5. Gardening or yard work 121 23 36 20 21 44 7 2.18
6. Caring for family members 124 49 39 7 5 39 10 1.23
7. Attending social events 146 54 38 5 3 34 8 1.06
8. Getting around in home 150 58 37 3 1 29 0 0.90
9. Walking around outside 150 44 42 11 3 37 2 1.30
10. Leisure outside of home 142 57 35 5 4 31 3 0.99
11. Hobbies 129 47 43 10 9 41 4 1.56
12. Physical recreation 143 20 45 24 11 49 7 2.07
13. Traveling out of town 142 39 47 8 6 49 5 1.42
14. Working at a job 108 32 39 12 17 39 6 1.82
* The complete text of S-VLA items is shown in Supplementary Appendix A (available in the online version of this article at http://onlinelibrary.
wiley.com/journal/10.1002/(ISSN)2151-4658). S-VLA  shortened version of the Valued Life Activities disability and accommodations scale.
† Scoring: difﬁculty  0 and no accommodations: score  0; difﬁculty  0 and any accommodations: score  1; difﬁculty  1 (some difﬁculty),
regardless of accommodations: score 2; difﬁculty 2 (a lot of difﬁculty), regardless of accommodations: score 3; difﬁculty 3 (unable to perform),
regardless of accommodations: score  4.
Table 3. S-VLA scale characteristics*
Total
(n  150)
Sex Duration of RA
Women
(n  111)
Men
(n  39) P†
<25 months
(n  18)
>25 months
(n  132) P†
S-VLA score, mean  SD 1.42  0.92 1.52  0.92 1.16  0.88 0.03 1.21  0.92 1.45  0.92 0.30
No. of S-VLA activities
rated, mean  SD
12.9  1.4 12.8  1.3 13.0  1.5 0.57 13.0  1.3 12.8  1.4 0.65
Cronbach’s  0.95 0.95 0.94 0.96 0.95
* S-VLA  shortened version of the Valued Life Activities disability and accommodations scale; RA  rheumatoid arthritis.
† P from t-test comparing women vs. men or 25 months vs. 25 months.
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engage in the activity in question. All items were rated as
addressing the activity domain well or extremely well.
Phase 3. Internal consistency of the S-VLA was excel-
lent (Cronbach’s  0.95) (Table 3), item-total correlations
ranged from 0.64–0.83, and alpha coefﬁcients did not
improve after omitting any of the 14 items. Time needed to
complete the S-VLA ranged from 2–4 minutes, with older
patients and those with impaired ability to write taking
longer than younger and/or less impaired patients. Forty-
two (84%) of 50 subjects asked to complete the S-VLA for
test–retest analysis returned their questionnaires. Krip-
pendorff’s alpha for individual items ranged from 0.58–
0.85. Correlation between initial and 2-week responses
was 0.92; the corresponding Krippendorff’s alpha was 0.91.
Results from bifactor assessment of unidimensionality
showed that, in comparison to the single-factor model,
loadings for the general factor in the bifactor model shrank
somewhat (a phenomenon also observed by Reise et al
[25]), but no loading of a variable differed by more than
12%. The ratio of the eigenvalue of the general factor to the
largest eigenvalue of the group factors was 7.2. The only
group factor loadings above 0.4 were on items 8 and 9, the
2 walking items. Together, these results support the use of
the mean item score as the S-VLA score.
Ratings for all items spanned the response scale, indi-
cating adequate variability in responses (Table 4). Respon-
dents reported accommodations on 29–52% of activities.
Reported use of accommodations for speciﬁc activities
ranged from 0–10% among individuals reporting no difﬁ-
culty.
The S-VLA demonstrated excellent construct validity.
Signiﬁcant correlations with all other measures in hypoth-
esized directions were found (Table 5). While these corre-
lations were strong, ranging from 0.65–0.82, they indi-
cated that, at best, the correlated measures accounted for
approximately 66% of the variation in S-VLA scores.
A signiﬁcant difference in S-VLA scores was noted be-
tween men and women (Table 3). This difference paral-
leled a signiﬁcant difference between men and women on
other measures of functioning, such as the HAQ and the
physical function subscale of the SF-36. Overall, there was
no signiﬁcant difference in the number of items rated “I
don’t do this for reasons unrelated to my RA” by sex. For
speciﬁc items, bias by sex did not appear to be present,
with one exception: a larger proportion of women did not
rate the item querying difﬁculty with work (women: 32%,
men: 15%; P  0.06). There were no substantive differ-
ences in the construct validity analyses between men and
women (Table 5).
S-VLA scores of individuals with early and longer du-
ration RA were also compared; no signiﬁcant differences
were noted (Table 3), nor were differences noted in scores
on other measures of functioning between these 2 groups.
Only 1 item appeared to be rated differently by the 2
groups: “taking care of family members” was rated not
applicable by a larger portion of those with longer disease
duration (early RA: 0%, longer duration: 19.7%; P 0.04).
Construct validity analyses yielded correlations with other
measures in the expected directions, although for 2 mea-
sures (APaQ and SF-36 physical functioning), the correla-
tion coefﬁcients were quite different for individuals with
early compared with longer duration RA. The reason for
this difference is unknown, but may be at least partially
due to the small number of individuals with early disease.
DISCUSSION
A short version of the VLA has been developed, which can
provide a brief assessment of disability in a broad range of
life activities in individuals with RA. Based on phase 1
analyses, the S-VLA accurately represents results obtained
with the longer version of the VLA scale. Phase 2 analyses
indicate that S-VLA items were comprehensible to indi-
viduals with RA and accurately represented the impact of
RA on their functioning in a number of key areas ranging
from work and self-care to travel and hobbies. Phase 3
analyses support the reliability and validity of the S-VLA.
Both internal consistency and 2-week test–retest reliability
were high. Correlations with other measures support the
construct validity of the S-VLA.
One primary goal in constructing the S-VLA was to
maintain coverage of the spectrum of obligatory, com-
mitted, and discretionary activities. The ﬁnal version of
the S-VLA taps functioning in 3 obligatory activities (tak-
ing care of basic needs, getting around inside home,
walking just to get around outside the home), 5 com-
Table 5. Phase 3: assessment of construct validity and correlations between S-VLA scores and other measures*
HAQ RADAI
SAWS
total
SAWS
abilities APaQ SF-36 PCS
SF-36 physical
functioning
SF-36 role
physical
SF-36 social
functioning
Total sample 0.81 0.71 0.81 0.82 0.65 0.78 0.80 0.67 0.72
By sex
Women (n  111) 0.81 0.67 0.89 0.82 0.65 0.77 0.79 0.68 0.74
Men (n  39) 0.78 0.82 0.83 0.82 0.65 0.78 0.82 0.60 0.71
By RA duration
25 months (n  18) 0.81 0.69 0.82 0.84 0.84 0.89 0.94 0.67 0.81
25 months (n  132) 0.81 0.72 0.81 0.82 0.65 0.76 0.78 0.68 0.75
* For the S-VLA, HAQ, RADAI, SAWS, and APaQ, higher scores reﬂect worse functioning. For the SF-36 scales, higher scores reﬂect better functioning.
S-VLA  shortened version of the Valued Life Activities disability and accommodations scale; HAQ  Health Assessment Questionnaire; RADAI 
Rheumatoid Arthritis Disease Activity Index; SAWS  Satisfaction with Abilities and Well-being Scale; APaQ  Activity Participation Questionnaire;
SF-36  Short-Form-36 health survey; PCS  physical component summary; RA  rheumatoid arthritis.
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mitted activities (meal preparation, light housework,
heavier housework, caring for family members, working
at a job), and 6 discretionary activities (gardening or
yard work, attending social events, leisure outside the
home, hobbies, physical recreation, and traveling out of
town). The inclusion of discretionary activities is particu-
larly important, as these are typically not measured in
other disability instruments, but appear to be the areas of
functioning that are affected earliest in the disablement
process (11).
An important innovation of the VLA, and by extension
the S-VLA, is incorporation of the use of accommoda-
tions. The HAQ measures 2 forms of accommodation: use
of assistive devices and personal assistance. Use of other
behavioral accommodations, such as limiting activities or
taking more time to perform them, to improve functioning
or reduce disability appears to be even more common than
use of devices or assistance (10), yet no other disability
measures include assessment of such behavioral accom-
modations. The importance of including accommodation
use is underscored by the ﬁnding that individuals may
report the use of accommodations without reporting difﬁ-
culty in an activity, and that such “subclinical disability”
identiﬁes individuals who are at high risk for functional
decline (27–29).
One limitation to the current analysis is that no esti-
mates of responsiveness or sensitivity to change can be
made. The long form of the VLA questionnaire demon-
strated a high degree of sensitivity to change in a lupus
sample (12), and other studies have found that VLA dis-
ability is more strongly linked to quality of life, satis-
faction with functioning, perceived health status, and
changes in psychological status than basic levels of func-
tioning, such as that measured by the HAQ (30–34).
While the S-VLA has yet to be tested in this fashion, its
extremely high correlation with VLA scores suggests that
similar performance and relationships may be found. As
the S-VLA queries difﬁculty in a broad range of activities,
particularly discretionary activities that may be affected
earliest in the disablement process, in addition to the use
of behavioral accommodations that may signal preclinical
disability (35), it may be especially sensitive to early
changes in functioning. We could not examine this ques-
tion directly in the current study, however, because of
the relatively small number of individuals in phase 3
who had earlier disease. It may also be useful in the future
to examine the performance of the S-VLA in relation to
other measures of functioning, such as the Rheumatoid
Arthritis Outcomes Score (36), and other measures of RA
disease activity, such as the Disease Activity Score (22).
The items measured by the S-VLA may be closer to the
functional expectations of individuals with RA, especially
those with early disease, than measures such as the HAQ.
For example, when persons with RA were asked what
activities were affected by RA that most bothered them or
what activities they most wanted to improve, only approx-
imately one-half of the functions or activities mentioned
were covered by the HAQ (37). In addition, disability in
discretionary activities, speciﬁcally social and recreational
activities, appears to be strongly linked to the onset of
depressive symptoms (31). Advances in pharmacologic
treatment have led to higher expectations regarding func-
tioning and overall quality of life. Patients want to move
beyond moderate symptom relief and regain indepen-
dence and valued activities such as physically demanding
hobbies and recreation. This very point was made in our
phase 2 interviews in which the item pertaining to par-
ticipating in physical recreation activities received a
higher rating of relevance than any other activities que-
ried, including basic activities of daily living.
In summary, the S-VLA is a short, valid, and reliable
instrument assessing a broad range of life activities and
use of behavioral accommodations that may prove useful
for monitoring disability among individuals with RA. The
brevity of the S-VLA makes it “user friendly” for both
clinical and research settings, and the current analyses
support its use in early and later disease. While additional
studies are needed to assess its validity and responsive-
ness to change, it appears to be a promising new, brief
measure of disability among individuals with RA that
addresses important aspects of functioning not currently
measured by other instruments.
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